NASDAQ:CALA Calithera Biosciences (CALA) Stock Price, News & Analysis $0.0020 0.00 (0.00%) As of 06/10/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Calithera Biosciences Stock (NASDAQ:CALA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Calithera Biosciences alerts:Sign Up Key Stats Today's Range$0.0020▼$0.002050-Day Range N/A52-Week Range$0.00▼$0.05Volume50 shsAverage Volume16,732 shsMarket Capitalization$9.74 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Read More… Calithera Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreCALA MarketRank™: Calithera Biosciences scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Calithera Biosciences. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.43% of the float of Calithera Biosciences has been sold short.Short Interest Ratio / Days to CoverCalithera Biosciences has a short interest ratio ("days to cover") of 97, which indicates bearish sentiment.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCalithera Biosciences does not currently pay a dividend.Dividend GrowthCalithera Biosciences does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.11 Percentage of Shares Shorted0.43% of the float of Calithera Biosciences has been sold short.Short Interest Ratio / Days to CoverCalithera Biosciences has a short interest ratio ("days to cover") of 97, which indicates bearish sentiment.Change versus previous month News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for CALA on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Calithera Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Calithera Biosciences is held by insiders.Read more about Calithera Biosciences' insider trading history. Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CALA Stock News HeadlinesCalithera Biosciences Inc (CALA)November 23, 2024 | investing.comPrimecap Management Portfolio Exposed: Top Holdings RevealedApril 26, 2024 | msn.comWant to front-run Warren Buffett? A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.June 12, 2025 | Golden Portfolio (Ad)Arcus Biosciences Inc (RCUS)February 24, 2024 | uk.investing.comChristina CalaAugust 12, 2023 | npr.orgCalithera Biosciences cancels special meeting due to lack of quorumJune 29, 2023 | seekingalpha.comCALA - Calithera Biosciences, Inc.June 1, 2023 | finance.yahoo.comCalithera Biosciences, Inc.: Calithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 20, 2023 | finanznachrichten.deSee More Headlines CALA Stock Analysis - Frequently Asked Questions How have CALA shares performed this year? Calithera Biosciences' stock was trading at $0.0001 at the beginning of the year. Since then, CALA stock has increased by 1,900.0% and is now trading at $0.0020. View the best growth stocks for 2025 here. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($3.00) EPS for the quarter, topping analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter. When did Calithera Biosciences' stock split? Calithera Biosciences shares reverse split on the morning of Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX) and First Solar (FSLR). Company Calendar Last Earnings11/08/2021Today6/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALA CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees60Year Founded2010Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,870,000Free Float4,550,000Market Cap$9.74 thousand OptionableNot Optionable Beta-2.56 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CALA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored2025 Market Crash50-Year Legend: Here's The Day Stocks Likely Crash Investing legend finds best cycle indicator during 50-ye...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calithera Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.